Dong-Seok Yim
He is currently working as professor and chairperson at the Dept. of Pharmacology of The
Catholic University of Korea, College of Medicine and the Dept. of Clinical Pharmacology of
Seoul St. Mary’s Hospital in Seoul. After graduating from Seoul National University (SNU),
College of Medicine in 1992 (M.D.), he got four years’ training of clinical pharmacology at the
graduate school of SNU Ph.D.). His master’s degree thesis on the population PK of phenytoin in
Korean patients then was the first publication based upon the mixed effect modeling and
simulation in Korea. After serving at Korea FDA for three years to fulfill military duty, he got two
years’ international fellowship at the Center for Drug Development Science (CDDS) of
Georgetown University (Director: Carl Peck). During the fellowship, he also worked as a visiting
scientist at CDER, FDA. A population PK-PD project on glucose-HbA1c model and a simulation
to compare the conventional and individual bioequivalence study data were projects led by him
at CDER. Back in Korea since 2005, he has been leading his PK-PD team and Phase I clinical
trial unit of Clinical Research Cooperating Center (CRCC) of Catholic Univ., one of the regional
clinical trial centers designated by Korean government. In 2006, he fouunded the PAGK
(population approach group in Korea) with his collegaues to accelerate the education of
pharmacometrics in the academia and industry in Korea. As a clinical pharmacologist and
pharmacometrician, he has been publishing many research articles on the PK/PD of antibiotics,
anticancer and cardiovascular drugs etc. PK-PD guided adaptive phase I trial of an anticancer
drug is one of research topics he is now performing in cooperation with his colleague clinician.